التفاصيل البيبلوغرافية
| العنوان: |
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial |
| المؤلفون: |
Batmunkh, Tsetsegsaikhan, Moore, Kerryn A., Thomson, Helen, Altangerel, Bolor, Amraa, Otgonjargal, Avaa, Naranbaatar, Batbayar, Lkhagvagaram, Batsukh, Khishigjargal, Bright, Kathryn, Burentogtokh, Tsogjargal, Ha Do, Lien Anh, Dorj, Gantuya, Hart, John D., Javkhlantugs, Khulan, Jigjidsuren, Sarantsetseg, Justice, Frances, Li, Shuo, Licciardi, Paul V., Mashbaatar, Khaliunaa, Mazarakis, Nadia, Neal, Eleanor F.G., Nguyen, Cattram Duong, Ochirbat, Batbayar, Tsolmon, Bilegtsaikhan, Tuya, Alimaa, Surenjav, Unursaikhan, von Mollendorf, Claire, Mulholland, Kim |
| المصدر: |
In The Lancet Regional Health - Western Pacific January 2024 42 |
| قاعدة البيانات: |
ScienceDirect |
Full Text via ClinicalKey 
Full Text Finder